Bangkok Genomics Innovation PCL (BKK:BKGI)

Market Cap	816.00M -30.6%
Revenue (ttm)	379.51M +12.4%
Net Income	45.35M -9.6%
EPS	0.08 -14.5%
Shares Out	600.00M
PE Ratio	17.99
Forward PE	n/a
Dividend	0.05 (3.68%)
Ex-Dividend Date	May 6, 2026

Volume	1,400
Average Volume	190,589
Open	1.350
Previous Close	1.350
Day's Range	1.350 - 1.360
52-Week Range	1.110 - 1.940
Beta	1.14
RSI	51.10
Earnings Date	May 15, 2026

About BKK:BKGI

Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand. The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand, preimplantation chromosomal abnormality and thalassemia carrier gene screening, infectious disease group analysis, and monkeypox virus analysis. It also provides other screening tests, such as cancer-related gene screening to predict the risk of inherited cancer, monitor treatment, select drugs that are appropriate for one's ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Thailand
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: BKGI

Financial Performance

In 2025, BKK:BKGI's revenue was 379.51 million, an increase of 12.42% compared to the previous year's 337.59 million. Earnings were 45.35 million, a decrease of -9.61%.